TuHURA Biosciences, Inc. | WebDisclosure

Basculer en Français

8232	Companies
111127	Keywords
52853	Articles
61004	Press releases

Headlines Articles Press releases TuHURA Biosciences, Inc.

Home
Companies
TuHURA Biosciences, Inc.

PRESS RELEASE

published on 06/03/2024 at 14:35, 5 months 5 days ago

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
TuHURA and Kintara announce positive results from TuHURA's Phase 1b trial evaluating IFx-2.0 in ICI naïve patients with advanced MCC and cSCC, overcoming resistance to ICI therapy. Data presented at 2024 ASCO Annual Meeting

Phase 1b Trial TuHURA Kintara IFx-2.0 Resistance To ICI Therapy
BRIEF

published on 04/03/2024 at 13:05, 7 months 5 days ago

Kintara Therapeutics et TuHURA Biosciences annoncent un accord de fusion pour faire progresser le pipeline d'oncologie

Accord De Fusion Thérapeutique En Oncologie Essais De Phase 3 Résistance À L'immunothérapie Projections Financières
BRIEF

published on 04/03/2024 at 13:05, 7 months 5 days ago

Kintara Therapeutics and TuHURA Biosciences Announce Merger Agreement to Advance Oncology Pipeline

Merger Agreement Oncology Therapeutics Phase 3 Trials Immunotherapy Resistance Financial Projections
PRESS RELEASE

published on 04/03/2024 at 13:00, 7 months 5 days ago

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
TuHURA and Kintara announce merger for advancing late-stage oncology pipeline with focus on personalized cancer vaccines and bi-functional ADCs. $31 million funding secured for operations till late 2025. Joint conference call scheduled for April 3, 2024

Merger Personalized Cancer Vaccines TuHURA Kintara Oncology Pipeline
PRESS RELEASE

published on 02/07/2024 at 16:00, 9 months 1 day ago

TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development
TuHURA Biosciences, Inc. appoints Dr. Dennis Yamashita as Chief Scientific Officer and Head of Discovery Research and Early Development to advance novel personalized cancer vaccines and bi-functional antibody drug conjugates. Dr. Yamashita brings over 30 years of experience in R&D drug discovery and development

TuHURA Biosciences Dr. Dennis Yamashita Personalized Cancer Vaccines Bi-functional Antibody Drug Conjugates Immuno-oncology

Accesswire

Published on 11/08/2024 at 18:15, 26 minutes ago

AccreditedEvents.com Presents High Performance Battery (HPB) for Filming on New to The Street at NYSE, Followed by Investor Event at Hudson Yards, NYC, on 11/11
Published on 11/08/2024 at 18:05, 36 minutes ago

Polaris Renewable Energy Announces Corporate and Bond Instrument Credit Rating
Published on 11/08/2024 at 17:31, 1 hour 10 minutes ago

Alphinat Announces a Profit of $803 for Quarter Ended February 29, 2024
Published on 11/08/2024 at 16:00, 2 hours 41 minutes ago

MANAMAURI, the High-Quality Energy Drink Brand, Joins EastBridge Global Investments for Major International Expansion
Published on 11/08/2024 at 15:45, 2 hours 56 minutes ago

Multi-Billion Dollar REIT in Utah

View all ACCESSWIRE

EQS Group

Published on 11/08/2024 at 18:35, 5 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/08/2024 at 18:20, 20 minutes ago

ENCAVIS achieves results in the first three quarters of 2024 below the figures for the same period of the previous year due to unforeseeable events and adjusts guidance for the current financial year
Published on 11/08/2024 at 18:15, 25 minutes ago

EQS-Adhoc: ENCAVIS AG
Published on 11/08/2024 at 18:02, 38 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/08/2024 at 18:00, 40 minutes ago

2CRSi SA: Provision of the Financial Report

Les Echos

Published on 11/08/2024 at 18:00, 41 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 11/08/2024 at 18:00, 41 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 11/08/2024 at 17:52, 49 minutes ago

Total number of voting rights and shares making up the share capital at October 31, 2024
Published on 11/08/2024 at 17:52, 49 minutes ago

Capital et droits de vote au 31 octobre 2024
Published on 11/08/2024 at 17:45, 56 minutes ago

CHARGEURS - Voting rights monthly statement as of October 31st, 2024

View all LES ECHOS COMFI WIRE